

PT Isolated polypeptide with a human transport protein sequence is useful
 PT for the diagnosis, prevention and treatment of disorders associated
 PT with the immune, reproductive and cardiovascular systems -
 XX
 XX
 XX Claim 2; Page 108-109; 165pp; English.
 XX
 XX The present invention provides the protein and coding sequences for 43
 CC novel human transport proteins (designated TPTs). These can be used in
 CC the diagnosis and treatment of transport, metabolic, neurological,
 CC reproductive, cardiovascular and immune disorders, and cell proliferative
 CC disorders such as cancer.
 XX
 XX Sequence: 374 AA;

Query Match 100.0%; Score 1345; DB 22; Length 374;
 Best Local Similarity 100.0%; Pred. No. 3.7e-144; Indels 0; Gaps 0;
 Matches 261; Conservative 0; Mismatches 0;
 QY 1 MESKMGELPLDINIQEPRWDQSTFLGRARHFFVTDPNLLSGAQLASRNIVONTYRAG 60
 DB 1 MESKMGELPLDINIQEPRWDQSTFLGRARHFFVTDPNLLSGAQLASRNIVONTYRAG 60
 QY 61 VTPGTTEDQLWRAKYVYDSAFPHDTCCKVLLGRMSAQVPMWMTTCMLTFYRKPTTV 120
 DB 61 VTPGTTEDQLWRAKYVYDSAFPHDTCCKVLLGRMSAQVPMWMTTCMLTFYRKPTTV 120
 QY 121 VPMQWNSFNAINVYNSRSGDPTITVRLGTAVSATTGAVATAGLKSUTGKLPLVNG 180
 DB 121 VPMQWNSFNAINVYNSRSGDPTITVRLGTAVSATTGAVATAGLKSUTGKLPLVNG 180
 QY 181 RVPPFAAANAANCINIPLMQRELQVGPVADAGORGLGYSVTAAGQIFQVWISRICMA 240
 DB 181 RVPPFAAANAANCINIPLMQRELQVGPVADAGORGLGYSVTAAGQIFQVWISRICMA 240
 QY 241 IPMAIPIPLIMDTLSEKDFLK 261
 DB 241 IPMAIPIPLIMDTLSEKDFLK 261

RESULT 7

AB41589
 ID AB41589 standard; Protein; 251 AA.

XX
 AC AB41589;

XX
 DT 08-FEB-2001 (first entry)

XX
 DE Human ORFX ORP1353 polypeptide sequence SEQ ID NO:2706.

XX Human; open reading frame; ORFX; detection; cytostatic; hepatotropic;
 KW vulnary; antipsoristic; antiparkinsonian; nootropic; neuroprotective;
 KW anticonvulsant; osteopathic; antiarthritic; immunosuppressant; cardiant;
 KW immunostimulant; thrombolytic; coagulant; vasotropic; antidiabetic;
 KW hypotensive; dermatological; immunosuppressive; antiinflammatory;
 KW antiviral; antibacterial; antifungal; antirheumatic; antichyroid;
 KW antianemic; gene therapy; cancer; proliferative disorder; hypertension;
 KW neurodegenerative disease; osteoarthritis; graft vs host disease;
 KW cardiovascular disease; diabetes mellitus; hypothyroidism; SCID; AIDS;
 KW cholesterol ester storage; systemic lupus erythematosus; infection;
 KW severe combined immunodeficiency; malaria; autoimmune disorder; asthma;
 KW allergy; aplastic anaemia; nocturnal haemoglobinuria; burn; wound;
 KW bone damage; cartilage damage; antiinflammatory disease; coagulation;
 KW thrombosis; contraceptive.

XX Homo sapiens.

XX MO2000058473-A2.

XX 05-OCT-2000.

XX 31-MAR-2000; 2000WO-0508621.

XX 31-MAR-1999; 99US-0127607.

PR 02-APR-1999; 99US-0127636.
 PR 05-APR-1999; 99US-0127728.
 PR 30-MAR-2000; 2000US-0540763.

XX (CURA-) CURAGEN CORP.

XX Shimketa RA, Leach M;

XX WPI; 2000-602362/57.

XX N-PSDB; AAC75798.

XX Novel nucleic acids and peptides derived from open reading frame X,
 PT useful for treating e.g. cancers, proliferative disorders,
 PT neurodegenerative disorders and cardiovascular disease -

XX Claim 11; Page 1942-1943; 5507pp; English.

XX AAC74446 to AAC77606 encode the proteins given in AAB40237 to AAB43397,
 CC which represent the human ORFX open reading frames 1 to 3161. The ORFX
 CC sequences have activities such as: cytostatic; hepatotropic; vulnary;
 CC antipsoristic; antiparkinsonian; nootropic; neuroprotective;
 CC osteopathic; anticonvulsant; antiarthritic; immunosuppressant;
 CC immunostimulant; cardiant; thrombolytic; coagulant; vasotropic;
 CC antidiabetic; hypotensive; dermatological; immunosuppressive;
 CC antiinflammatory; antibacterial; antiviral; antifungal; antirheumatic;
 CC antichyroid; and antianemic. The sequences can be used for determining
 CC the presence of or predisposition to, or preventing or treating
 CC pathological conditions associated with an ORFX protein in gene therapy
 CC nucleic acids can be used to express ORFX proteins in gene therapy
 CC vectors. The proteins and nucleic acids may be used to treat cancers,
 CC proliferative disorders, neurodegenerative disorders, osteoarthritis,
 CC graft vs host disease, cardiovascular disease, diabetes mellitus,
 CC hypertension, hypothyroidism, cholesterol ester storage, systemic lupus
 CC erythematosus, severe combined immunodeficiency (SCID), AIDS, viral,
 CC bacterial or fungal infection, malaria, autoimmune disorders, asthma,
 CC allergies, aplastic anaemia, burns, wounds, bone and cartilage damage,
 CC nocturnal haemoglobinuria, antiinflammatory diseases; to enhance
 CC coagulation; to inhibit thrombosis; and as a contraceptive.

XX Sequence 251 AA;

Query Match 94.3%; Score 1289; DB 21; Length 251;

Best Local Similarity 98.0%; Pred. No. 9.2e-136;

Matches 246; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 1 MESKMGELPLDINIQEPRWDQSTFLGRARHFFVTDPNLLSGAQLASRNIVONTYRAG 60

DB 1 MESKMGELPLDINIQEPRWDQSTFLGRARHFFVTDPNLLSGAQLASRNIVONTYRAG 60

QY 61 VTPGTTEDQLWRAKYVYDSAFPHDTCCKVLLGRMSAQVPMWMTTCMLTFYRKPTTV 120

DB 61 VTPGTTEDQLWRAKYVYDSAFPHDTCCKVLLGRMSAQVPMWMTTCMLTFYRKPTTV 120

QY 121 VPMQWNSFNAINVYNSRSGDPTITVRLGTAVSATTGAVATAGLKSUTGKLPLVNG 180

DB 121 VPMQWNSFNAINVYNSRSGDPTITVRLGTAVSATTGAVATAGLKSUTGKLPLVNG 180

QY 181 RVPPFAAANAANCINIPLMQRELQVGPVADAGORGLGYSVTAAGQIFQVWISRICMA 240

DB 181 RVPPFAAANAANCINIPLMQRELQVGPVADAGORGLGYSVTAAGQIFQVWISRICMA 240

QY 241 IPMAIPIPLIM 251

DB 241 IPMAIPIPLIM 251

RESULT 8

ABG20175

ID ABG20175 standard; Protein; 397 AA.

XX ABG20175;

XX 18-FEB-2002 (first entry)